Additionally, IGF2BP2 is overexpressed in cisplatin-resistant SCLC, where its effects on Spon2 transcripts activate the IGF2BP2-SPON2 and PI3K/Akt proliferation signaling pathways (Figure 1) [36,37]. This evidence concerns the gene IGF2BP2 and small cell lung carcinoma.